Across TCGA pan-cancer cohorts, RPL35AP12 RNA is linked to patient survival in 8 of 34 cancer types, making it the most broadly survival-associated RPL35AP12 data layer.
The strongest signal is observed in mesothelioma (MESO), where higher RPL35AP12 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL35AP12 expression acts as an unfavorable survival marker, although some lineages such as LUSC show a favorable association.
MESO, KIRP, and READ are the cancer types where RPL35AP12 RNA most reproducibly stratifies survival.
RNA survival associations by lineage
Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.